Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Unity Biotechnology Inc (UBX)

Unity Biotechnology Inc (UBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,444
  • Shares Outstanding, K 17,212
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,990 K
  • EBIT $ -28 M
  • EBITDA $ -25 M
  • 60-Month Beta 0.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.46
  • Most Recent Earnings $-0.43 on 04/22/25
  • Next Earnings Date 08/05/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.30
  • Number of Estimates 1
  • High Estimate -0.30
  • Low Estimate -0.30
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +3.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2000 +0.05%
on 07/08/25
1.1300 -82.29%
on 06/10/25
-0.4809 (-70.62%)
since 06/06/25
3-Month
0.2000 +0.05%
on 07/08/25
1.2300 -83.73%
on 05/05/25
-0.6832 (-77.35%)
since 04/08/25
52-Week
0.2000 +0.05%
on 07/08/25
3.1000 -93.55%
on 01/23/25
-1.1299 (-84.95%)
since 07/08/24

Most Recent Stories

More News
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates

UBX : 0.2001 (-33.41%)
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

UBX : 0.2001 (-33.41%)
UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME

UBX : 0.2001 (-33.41%)
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

UBX : 0.2001 (-33.41%)
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema

UBX : 0.2001 (-33.41%)
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

UBX : 0.2001 (-33.41%)
UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors

UBX : 0.2001 (-33.41%)
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

UBX : 0.2001 (-33.41%)
UNITY Biotechnology Reports Granting of New Employment Inducement Award

UBX : 0.2001 (-33.41%)
UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer

UBX : 0.2001 (-33.41%)

Business Summary

UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company's product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States.

See More

Key Turning Points

3rd Resistance Point 0.3981
2nd Resistance Point 0.3584
1st Resistance Point 0.2793
Last Price 0.2001
1st Support Level 0.1605
2nd Support Level 0.1208
3rd Support Level 0.0417

See More

52-Week High 3.1000
Fibonacci 61.8% 1.9922
Fibonacci 50% 1.6500
Fibonacci 38.2% 1.3078
Last Price 0.2001
52-Week Low 0.2000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar